NYSEAMERICAN:CVM

CEL-SCI Stock Forecast, Price & News

$22.13

-0.04 (-0.18 %)

(As of 06/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$21.45

▼

$22.36

50-Day Range

$11.05

▼

$15.42

52-Week Range

$10.76

▼

$40.91

Volume467,368 shs

Average Volume1.07 million shs

Market Capitalization$910.18 million

P/E RatioN/A

Dividend YieldN/A

Beta2.24

30 days | 90 days | 365 days | Advanced Chart

Receive CVM News and Ratings via Email

Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter.

About CEL-SCI

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.

CEL-SCI (NYSEAMERICAN:CVM) Trading 4.1% Higher
June 18, 2021 | americanbankingnews.com

Noteworthy Thursday Option Activity: CVM, FGEN, DIS - Nasdaq
June 17, 2021 | nasdaq.com

Cel-Sci Stock Shows Market Leadership With Jump To 81 RS Rating - Investor's Business Daily
June 17, 2021 | investors.com

Cel-Sci Stock Shows Market Leadership With Jump To 81 RS Rating
June 17, 2021 | finance.yahoo.com

Cel-Sci Shows Market Leadership With Jump To 81 RS Rating - Investor's Business Daily
June 17, 2021 | investors.com

CEL-SCI (NYSEAMERICAN:CVM) Shares Gap Up to $20.91
June 16, 2021 | americanbankingnews.com

CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering - Business Wire
June 11, 2021 | businesswire.com

CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering
June 11, 2021 | finance.yahoo.com

48 Stocks Moving In Wednesday's Mid-Day Session Benzinga - Benzinga
June 9, 2021 | benzinga.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:CVM
Previous Symbol
CUSIPN/A
CIK725363
Webwww.cel-sci.com
Phone+1-703-5069460
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual Sales$560,000.00
Price / Sales1,625.33
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.51 per share
Price / Book43.39

Profitability

EPS (Most Recent Fiscal Year)($0.74)
Net Income$-30,250,000.00
Net Margins-5,406.61%
Return on Equity-129.71%
Return on Assets-70.24%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares41,129,000
Market Cap$910.18 million
Next Earnings Date8/10/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

0.49 out of 5 stars

Medical Sector

1669th out of 2,105 stocks

Biological Products, Except Diagnostic Industry

181st out of 198 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for CEL-SCI.

1.8 Community Rank

Outperform Votes
CEL-SCI has received 129 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
CEL-SCI has received 227 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
CEL-SCI has received 63.76% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about CEL-SCI and other stocks. Vote “Outperform” if you believe CVM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CVM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
CEL-SCI does not currently pay a dividend.
Dividend Growth
CEL-SCI does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CEL-SCI insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $243,800.00 in company stock.
Percentage Held by Insiders
Only 12.60% of the stock of CEL-SCI is held by insiders.
Percentage Held by Institutions
Only 33.33% of the stock of CEL-SCI is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for CEL-SCI are expected to grow in the coming year, from ($0.64) to $1.05 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CEL-SCI is -24.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CEL-SCI is -24.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CEL-SCI has a P/B Ratio of 43.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

CEL-SCI (NYSEAMERICAN:CVM) Frequently Asked Questions

What stocks does MarketBeat like better than CEL-SCI?

Wall Street analysts have given CEL-SCI a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CEL-SCI wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is CEL-SCI's next earnings date?

CEL-SCI is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for CEL-SCI.

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSEAMERICAN:CVM) announced its quarterly earnings data on Sunday, May, 16th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.30. CEL-SCI had a negative net margin of 5,406.61% and a negative trailing twelve-month return on equity of 129.71%.
View CEL-SCI's earnings history.

How has CEL-SCI's stock price been impacted by Coronavirus (COVID-19)?

CEL-SCI's stock was trading at $9.74 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CVM shares have increased by 127.2% and is now trading at $22.13.
View which stocks have been most impacted by COVID-19.

When did CEL-SCI's stock split? How did CEL-SCI's stock split work?

CEL-SCI shares reverse split on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 14th 2017. An investor that had 100 shares of CEL-SCI stock prior to the reverse split would have 4 shares after the split.

Who are CEL-SCI's key executives?

CEL-SCI's management team includes the following people:

Mr. Geert R. Kersten, CEO, Principal Accounting & Financial Officer, Treasurer and Director (Age 62, Pay $825.53k)
Ms. Patricia B. Prichep, Sr. VP of Operations & Corp. Sec. (Age 70, Pay $383.35k)
Dr. Eyal Talor, Chief Scientific Officer (Age 65, Pay $317.48k)
Dr. Daniel H. Zimmerman, Sr. VP of Research & Cellular Immunology (Age 80, Pay $248.54k)
Mr. John Cipriano, Sr. VP of Regulatory Affairs (Age 79, Pay $237.04k)

Who are some of CEL-SCI's key competitors?

Some companies that are related to CEL-SCI include Allogene Therapeutics (ALLO), Relay Therapeutics (RLAY), BioCryst Pharmaceuticals (BCRX), NanoString Technologies (NSTG), Vericel (VCEL), Bavarian Nordic A/S (BVNRY), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Revolution Medicines (RVMD), Instil Bio (TIL), Rubius Therapeutics (RUBY), bluebird bio (BLUE), Kymera Therapeutics (KYMR), Alector (ALEC) and Cortexyme (CRTX).
View all of CVM's competitors.

What other stocks do shareholders of CEL-SCI own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CEL-SCI investors own include Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), Savara (SVRA), Molecular Templates (MTEM), Gilead Sciences (GILD), Heat Biologics (HTBX), Idera Pharmaceuticals (IDRA), VBI Vaccines (VBIV) and CymaBay Therapeutics (CBAY).

What is CEL-SCI's stock symbol?

CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."

Who are CEL-SCI's major shareholders?

CEL-SCI's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.39%), D. E. Shaw & Co. Inc. (3.05%), Geode Capital Management LLC (1.50%), Northern Trust Corp (0.97%), D.A. Davidson & CO. (0.81%) and Commonwealth Equity Services LLC (0.58%). Company insiders that own CEL-SCI stock include Geert R Kersten, John Cipriano, Patricia B Prichep and Peter R Young.
View institutional ownership trends for CEL-SCI.

Which institutional investors are selling CEL-SCI stock?

CVM stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Credit Suisse AG, Goldman Sachs Group Inc., Morgan Stanley, Ameriprise Financial Inc., BNP Paribas Arbitrage SA, AQR Capital Management LLC, and Alliancebernstein L.P..
View insider buying and selling activity for CEL-SCI or view top insider-selling stocks.

Which institutional investors are buying CEL-SCI stock?

CVM stock was acquired by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Citigroup Inc., Rafferty Asset Management LLC, BlackRock Inc., Geode Capital Management LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, and Russell Investments Group Ltd.. Company insiders that have bought CEL-SCI stock in the last two years include Geert R Kersten, Patricia B Prichep, and Peter R Young.
View insider buying and selling activity for CEL-SCI or or view top insider-buying stocks.

How do I buy shares of CEL-SCI?

Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CEL-SCI's stock price today?

One share of CVM stock can currently be purchased for approximately $22.13.

How much money does CEL-SCI make?

CEL-SCI has a market capitalization of $910.18 million and generates $560,000.00 in revenue each year. The company earns $-30,250,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

What is CEL-SCI's official website?

The official website for CEL-SCI is www.cel-sci.com.

Where are CEL-SCI's headquarters?

CEL-SCI is headquartered at 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States.

How can I contact CEL-SCI?

CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at +1-703-5069460 or via email at [email protected]

This page was last updated on 6/23/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here